Literature DB >> 22552047

The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting.

Yuanyuan Liang1, Donna P Ankerst, Ziding Feng, Rong Fu, Janet L Stanford, Ian M Thompson.   

Abstract

MATERIALS AND METHODS: Risks of prostate cancer (CaP) and high-grade CaP were evaluated using the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) in an age-stratified random sample of 1,021 Caucasian and African-American men with no previous diagnosis of CaP, aged 55-74 years, residing in King County, WA, USA.
RESULTS: Median PCPTRC risks of CaP (high-grade CaP) were 15.6% (1.2%), 18.7% (2.0%), 18.5% (2.2%), and 26.4% (5.1%) for 55-59, 60-64, 65-69, and 70-74-year-old men, respectively; 25.2% of men aged 55-59 had a 25% or greater PCPTRC risk of CaP; this increased to 53.1% in men aged 70-74; 9.4% of men aged 55-59 had a 6% or greater PCPTRC risk of high-grade CaP, increasing to 44.1% in men aged 70-74.
CONCLUSIONS: PCPTRC risk of CaP in a community of US males is high and confounded with overdetected cancers. In contrast, average community PCPTRC risk of high-grade disease is low and increases gradually by age and may better serve for counseling purposes.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  High-grade prostate cancer; Prostate Cancer Prevention Trial Risk Calculator (PCPTRC); Prostate cancer; Prostate specific antigen (PSA)

Mesh:

Year:  2012        PMID: 22552047      PMCID: PMC3426631          DOI: 10.1016/j.urolonc.2012.03.012

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  24 in total

1.  A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.

Authors:  Da-Long Cao; Ding-Wei Ye; Hai-Liang Zhang; Yao Zhu; Yi-Xuan Wang; Xu-Dong Yao
Journal:  Prostate       Date:  2010-10-18       Impact factor: 4.104

2.  Prediction models in cancer care.

Authors:  Andrew J Vickers
Journal:  CA Cancer J Clin       Date:  2011-06-23       Impact factor: 508.702

3.  The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience.

Authors:  D S Smith; P A Humphrey; W J Catalona
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

4.  Updating risk prediction tools: a case study in prostate cancer.

Authors:  Donna P Ankerst; Tim Koniarski; Yuanyuan Liang; Robin J Leach; Ziding Feng; Martin G Sanda; Alan W Partin; Daniel W Chan; Jacob Kagan; Lori Sokoll; John T Wei; Ian M Thompson
Journal:  Biom J       Date:  2011-11-17       Impact factor: 2.207

5.  External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population.

Authors:  Dipen J Parekh; Donna Pauler Ankerst; Betsy A Higgins; Javier Hernandez; Edith Canby-Hagino; Timothy Brand; Dean A Troyer; Robin J Leach; Ian M Thompson
Journal:  Urology       Date:  2006-12       Impact factor: 2.649

6.  Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy.

Authors:  Carvell T Nguyen; Changhong Yu; Ayman Moussa; Michael W Kattan; J Stephen Jones
Journal:  J Urol       Date:  2009-12-14       Impact factor: 7.450

7.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

8.  Predicting prostate cancer risk through incorporation of prostate cancer gene 3.

Authors:  Donna Pauler Ankerst; Jack Groskopf; John R Day; Amy Blase; Harry Rittenhouse; Brad H Pollock; Cathy Tangen; Dipen Parekh; Robin J Leach; Ian Thompson
Journal:  J Urol       Date:  2008-08-15       Impact factor: 7.450

9.  Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.

Authors:  Felix K Chun; Alexandre de la Taille; Hendrik van Poppel; Michael Marberger; Arnulf Stenzl; Peter F A Mulders; Hartwig Huland; Clement-Claude Abbou; Alexander B Stillebroer; Martijn P M Q van Gils; Jack A Schalken; Yves Fradet; Leonard S Marks; William Ellis; Alan W Partin; Alexander Haese
Journal:  Eur Urol       Date:  2009-03-13       Impact factor: 20.096

10.  Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.

Authors:  Monique J Roobol; F H Schröder; Jonas Hugosson; J Stephen Jones; Michael W Kattan; Eric A Klein; Freddie Hamdy; David Neal; Jenny Donovan; Dipen J Parekh; Donna Ankerst; George Bartsch; Helmut Klocker; Wolfgang Horninger; Amine Benchikh; Gilles Salama; Arnauld Villers; Stephen J Freedland; Daniel M Moreira; Andrew J Vickers; Hans Lilja; Ewout W Steyerberg
Journal:  World J Urol       Date:  2011-12-28       Impact factor: 4.226

View more
  1 in total

1.  Engaging African American Men as Citizen Scientists to Validate a Prostate Cancer Biomarker: Work-in-Progress.

Authors:  Karriem S Watson; Vida Henderson; Marcus Murray; Adam B Murphy; Josef Ben Levi; Tiffany McDowell; Alfreda Holloway-Beth; Pooja Gogana; Michael A Dixon; LeAndre Moore; Ivanhoe Hall; Alexander Kimbrough; Yamilé Molina; Robert A Winn
Journal:  Prog Community Health Partnersh       Date:  2019
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.